Your session is about to expire
← Back to Search
Interspinous Spacer
1 for Intermittent Claudication
N/A
Waitlist Available
Research Sponsored by Boston Scientific Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 24 months
Awards & highlights
No Placebo-Only Group
Summary
The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffering from at least 6 months of moderate spinal stenosis symptoms who have been unresponsive to conservative care.
Eligible Conditions
- Intermittent Claudication
- Lumbar Spinal Stenosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Subjects With Clinically Significant Improvement in Outcomes
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment1 Intervention
Interspinous Process Spacer Device
Group II: 2Active Control1 Intervention
Interspinous Process Spacer Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Superion™ Interspinous Spacer
2008
N/A
~400
Find a Location
Who is running the clinical trial?
VertiFlex, IncorporatedIndustry Sponsor
2 Previous Clinical Trials
180 Total Patients Enrolled
Boston Scientific CorporationLead Sponsor
744 Previous Clinical Trials
857,412 Total Patients Enrolled
2 Trials studying Intermittent Claudication
2,150 Patients Enrolled for Intermittent Claudication
Roshini JainStudy DirectorBoston Scientific Corporation
30 Previous Clinical Trials
25,908 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger